Literature DB >> 8774540

Seroprevalence of hepatitis B and C virus in two institutions caring for mentally handicapped adults.

M E Cramp1, H C Grundy, R M Perinpanayagam, D E Barnado.   

Abstract

Hepatitis B virus infection is common in institutions caring for the mentally handicapped. Hepatitis B virus and hepatitis C virus share routes of transmission but the prevalence of hepatitis C virus infection in this population is unknown. We have tested 101 patients from two institutions in South-East England caring for adults with mental handicap for the presence of hepatitis C antibody, hepatitis B core antibody, and if necessary hepatitis B surface antigen. None tested positive for hepatitis C antibody, but 43 had hepatitis B core antibody of whom 14 were chronic carriers positive for hepatitis B surface antigen. Unlike hepatitis B virus, hepatitis C virus infection appears to be uncommon in UK institutions.

Entities:  

Mesh：

Year:  1996        PMID： 8774540      PMCID： PMC1295856     

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


  15 in total

1.  Advances in hepatitis C: sero-epidemiology and natural history.

Authors:  M Yano
Journal:  J Gastroenterol Hepatol       Date:  1992 Sep-Oct       Impact factor: 4.029

2.  Community-acquired hepatitis C virus infection.

Authors:  F B Hollinger; H J Lin
Journal:  Gastroenterology       Date:  1992-04       Impact factor: 22.682

3.  [Hepatitis C virus infection in different risk groups and among blood donors].

Authors:  J L Martínez; J del Hierro; A Camarero; A Medarde; M T López; J Latasa
Journal:  Enferm Infecc Microbiol Clin       Date:  1991 Jun-Jul       Impact factor: 1.731

4.  Hepatitis C virus transmitted by human bite.

Authors:  G M Dusheiko; M Smith; P J Scheuer
Journal:  Lancet       Date:  1990-08-25       Impact factor: 79.321

5.  Intrafamilial transmission of hepatitis C virus.

Authors:  G Idéo; G Bellati; E Pedraglio; R Bottelli; T Donzelli; G Putignano
Journal:  Lancet       Date:  1990-02-10       Impact factor: 79.321

6.  Hepatitis C virus antibody.

Authors:  P P Mortimer; B J Cohen; P A Litton; E M Vandervelde; M F Bassendine; A M Brind; M H Hambling
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

7.  Development and distribution of hemagglutinating antibody against the hepatitis B antigen in institutionalized populations.

Authors:  W Szmuness; A M Prince; G F Etling; R Pick
Journal:  J Infect Dis       Date:  1972-11       Impact factor: 5.226

8.  Hepatitis C virus antibodies among risk groups in Spain.

Authors:  J I Esteban; R Esteban; L Viladomiu; J C López-Talavera; A González; J M Hernández; M Roget; V Vargas; J Genescà; M Buti
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

9.  Viral hepatitis, type B. Studies on natural history and prevention re-examined.

Authors:  S Krugman; L R Overby; I K Mushahwar; C M Ling; G G Frösner; F Deinhardt
Journal:  N Engl J Med       Date:  1979-01-18       Impact factor: 91.245

10.  Hepatitis C virus infection in the asymptomatic British blood donor.

Authors:  D J Mutimer; R F Harrison; K B O'Donnell; J Shaw; B A Martin; H Atrah; F A Ala; S Skidmore; S G Hubscher; J M Neuberger
Journal:  J Viral Hepat       Date:  1995       Impact factor: 3.728
View more
  3 in total

1.  Hepatitis A, B, and C.

Authors:  R Gilson; M G Brook
Journal:  Sex Transm Infect       Date:  2006-12       Impact factor: 3.519

2.  Sexually transmitted infection among adolescents receiving special education services.

Authors:  David S Mandell; Catharine C Eleey; Julie A Cederbaum; Elizabeth Noll; M Katherine Hutchinson; Loretta S Jemmott; Michael B Blank
Journal:  J Sch Health       Date:  2008-07       Impact factor: 2.118

3.  Hepatitis B virus infection among institutionalized mentally ill patients in Brazil.

Authors:  Tatiane Cinquini Moraes; Fabíola Souza Fiaccadori; Menira Souza; Tâmera Nunes Vieira Almeida; Marielton dos Passos Cunha; Ítalo de Araújo Castro; Divina das Dôres de Paula Cardoso
Journal:  Braz J Infect Dis       Date:  2015-09-09       Impact factor: 3.257
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.